BACKGROUND	The viral protease inhibitor ritonavir has the capacity to inhibit and induce the activity of cytochrome P450-3A ( CYP3A ) isoforms , leading to drug interactions that may influence the efficacy and toxicity of other antiretroviral therapies , as well as pharmacologic treatments of coincident or complicating diseases .\